Article

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS <sup>G12D</sup> -driven non-small cell lung cancer

2023-09-22

Abstract excerpt

<h4>Introduction</h4> KRAS G12C and KRAS G12D inhibitors represent a major translational breakthrough for non-small cell lung cancer (NSCLC) and cancer in general by directly targeting its most mutated oncoprotein. However, resistance to these small molecules has highlighted the need for rational combination partners necessitating a critical understanding of signaling downstream of KRAS mutant isoforms. <h4>Me...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 71807a62-1c91-5490-a7fe-867d2c117409
DOI: 10.1101/2023.09.20.558592

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS <sup>G12D</sup> -driven non-small cell lung cancerDOI 10.1101/2023.09.20.558592Read

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer.Semantic proximity Read

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read

KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.Semantic proximity Read

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.Semantic proximity Read

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.Semantic proximity Read

Evaluation of KRAS <sup>G12C</sup> Inhibitor Responses in Novel Murine KRAS <sup>G12C</sup> Lung Cancer Cell Line ModelsSemantic proximity Read

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read

PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung TumorigenesisSemantic proximity Read

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.Semantic proximity Read

Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.Semantic proximity Read

Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read